Functional defect in regulatory T cells in myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1274, Issue 1, 2012, Pages 68-76

  Thiruppathi, Muthusamy ^a   Rowin, Julie ^a   Li Jiang, Qin ^a   Sheng, Jian Rong ^a   Prabhakar, Bellur S ^a   Meriggioli, Matthew N ^a  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

FOXP3; GM CSF; Myasthenia gravis; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CELL ISOLATION; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MYASTHENIA GRAVIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UPREGULATION;

EID: 84871302507     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06840.x     Document Type: Article

References (58)

1. Meriggioli, M.N. & D.B. Sanders. 2009. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 8: 475-490.
2. Berrih, S., E. Morel, C. Gaud, et al. 1984. Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology 34: 66-71.
3. Roxanis, I., K. Micklem & N. Willcox. 2001. True epithelial hyperplasia in the thymus of early-onset myasthenia gravis: implications for immunopathogenesis. J. Neuroimmunol. 112: 163-173.
4. Giraud, M., C. Vandiedonck & H.J. Garchon. 2008. Genetic factors in autoimmune myasthenia gravis. Ann. N.Y. Acad. Sci. 1132: 180-192.
5. Landoure G., M.A. Knight, H. Stanescu, et al. 2012. A candidate gene for autoimmune myasthenia gravis. Neurology 79: 342-347.
6. Maniaol, A.H., A. Elsais, A.R. Lorentzen, et al. 2012. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One. 7(5): e36603. Epub 2012 May 9.
7. Protti, M.P., A. A. Manfredi, C. Straub, et al. 1990. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc. Natl. Acad. Sci. USA 87: 7792-7796.
8. Wang, Z.Y., D. K. Okita, J. Jr. Howard, et al. 1998. T-cell recognition of muscleacetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 50: 1045-1054.
9. Abramsky, O., A. Aharonov, C. Webb & S. Fuchs. 1975. Cellular immune response to acetylcholine receptor rich-fraction, in patients with myasthenia gravis. Clin. Exp. Immunol. 19: 11-16.
10. Richman, D.P., J.P. Antel, J.W. Patrick & B.G.W. Arnason. 1979. Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology 29: 291-296.
11. Hohlfeld, R., I. Kalies, B. Kohleisen, et al. 1986. Myasthenia gravis: stimulation of anti-receptor autoantibodies by autoreactive T cell lines. Neurology 36: 618-621.
12. Bouneaud, C., P. Kourilsky & P. Buosso. 2000. Impact of negative selection on the T cell repertoire reactive to a self peptide: a large fraction of T cell clones escapesclonal deletion. Immunity 13: 829-840.
13. Workman, C.J., A.L. Szymczak-Workman, L.W. Collison, et al. 2009. Thedevelopment and function of regulatory T cells. Cell. Mol. Life Sci. 66: 2603-2622.
14. Baecher-Allan, C. & D.A. Hafler. 2006. Human regulatory T cells and their role in autoimmune disease. Immunol. Rev. 212: 203-216.
15. Torgerson, T.R. 2006. Regulatory T cells in human autoimmune diseases. Springer Semin. Immunopathol. 28: 63-76.
16. Sakaguchi, S., M. Miyara, C.M. Costantino, et al. 2010. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10: 490-500.
17. Fontenot, J.D., M.A. Gavin & A.Y. Rudensky. 2003. FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat.Immunol. 4: 330-336.
18. Hori, S., T. Nomura & S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor FOXP3. Science 299: 1057-1061.
19. Buckner, J.H. 2010. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10: 849-859.
20. Moes, N., F. Rieux-Laucat, B. Begue, et al. 2010. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology 139: 770-778.
21. high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178: 2579-2588.
22. high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with areduced frequency of FOXP3-positive cells and reducedFOXP3 expression at the single-cell level. Immunology 123: 79-89.
23. Venigalla, R.K., T. Tretter, S. Krienke, et al. 2008. Reduced CD4+, CD25- T cell sensitivity to the suppressive function of CD4+, CD25high, CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58: 2120-2130.
24. Vargas-Rojas, M.I., J.C. Crispín, Y. Richaud-Patin, et al. 2008. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 17: 289-294.
25. Walker, L.S. 2009. Regulatory T cells overturned: the effectors fight back. Immunology 126: 466-474.
26. Iikuni, N., E.V. Lourenco, B.H. Hahn, et al. 2009. Regulatory T cells directly suppress B cells in systemic lupus erythematosis. J. Immunol. 183: 1518-1522.
27. Fattorossi, A., A. Battaglia, A. Buzzonetti, et al. 2005. Circulating and thymic CD4+CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116: 134-141.
28. Li, X., B.G. Xiao, J.Y. Xi, et al. 2008. Decrease of Foxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis. Clin. Immunol. 126: 180-188.
29. Masuda, M., M. Matsumoto, S. Tanaka, et al. 2010. Clinical implication of peripheral CD4+ CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J. Neuroimmunol. 225: 123-131.
30. Zhang, Y., H. Wang, L. Chi, et al. 2009. The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis. Immunol. Lett. 122: 52-57.
31. Huang, Y.M., R. Pirskanen, R. Giscombe, et al. 2004. Circulating CD4+CD25 +and CD4+CD25+Tcells in myasthenia gravis and in relation to thymectomy. Scand. J. Immunol. 59: 408-414.
32. Matsui, N., S. Nakane, F. Saito, et al. 2010. Undiminished regulatory T cells in the thymus of patients with myasthenia gravis. Neurology 74: 816-820.
33. Balandina, A., S. Lécart, P. Dartevelle, et al. 2005. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105: 735-741.
34. Lim, A.Y., P. Price, M.W. Beilharz, et al. 2006. Cell surface markers of regulatory T cells are not associated with increased forkheadbox p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy. Immunol. Cell. Biol. 84: 530-536.
35. Seddiki, N., B. Santner-Nanan, J. Martinson, et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203: 1693-1700.
36. Liu W., A.L. Putnam, Z. Xu-Yu, et al. 2006. CD127 expression inversely correlates with FOXP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203: 1701-1711.
37. low/- T cells in patients with myasthenia gravis. Clin. Immunol. 145: 209-223.
38. Voo, K.S., Y.H. Wang, F.R. Santori, et al. 2009. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc. Natl. Acad. Sci. USA 106: 4793-4798.
39. Xu, W.H., A.M. Zhang, M.S. Ren, et al. 2012. Changes of Treg-associated molecules on CD4(+)CD25(+) Treg cells in myasthenia gravis and effects of immunosuppressants. J. Clin. Immunol. 32: 975-983.
40. Baecher-Allan, C., E. Wolf & D.A. Hafler. 2006. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 176: 4622-4631.
41. Brocke, S., C. Brautbar, L. Steinman, et al. 1988. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J. Clin. Invest. 82: 1894-1900.
42. Miyara, M., Y. Yoshioka, A. Kitoh, et al. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
43. Sakaguchi, S., T. Yamaguchi, T. Nomura, et al. 2008. Regulatory T cells and immune tolerance. Cell. 133: 775-787.
44. Hoffmann, P., R. Eder, T.J. Boeld, et al. 2006. Only the CD45RA +subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108: 4260-4267.
45. d'Hennezel, E., E. Yurchenko, E. Sgouroudis, et al. 2011. Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3+ cells. J. Immunol. 186: 6788-6797.
46. Luther, C., E. Adamopoulou, C. Stoeckle, et al. 2009. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J. Immunol. 183: 841-848.
47. Kessel, A., H. Ammuri, R. Peri, et al. 2007. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 179: 5571-5575.
48. Hoffman P., R. Eder, L.A. Kunz-Schughart, et al. 2004. Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells. Blood 104: 895-903.
49. Earle, K.E., Q. Tang, X. Zhou, et al. 2005. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin. Immunol. 115: 3-9.
50. Hamilton, J.A. 2002. GM-CSF in inflammation and autoimmunity. Trends Immunol. 23: 403-408.
51. Ganesh, B.B., D.M. Cheatem, J.R. Sheng, et al. 2009. GMCSF-induced CD11c+CD8a- -dendritic cells facilitate FOXP3+ and IL-10 +regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int. Immunol. 21: 269-282.
52. Gaudreau, S., C. Guindi, M. Menard, et al. 2007. Granulocyte-macrophage colony stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of regulatory T cells. J. Immunol. 179: 3638-3647.
53. Sheng, J.R., L.C. Li, B.B. Ganesh, et al. 2006. Suppression of experimental autoimmune myasthenia gravis (EAMG) by granulocyte-macrophage colony-stimulating factor (GMCSF) is associated with an expansion of FOXP3+ regulatory T cells. J. Immunol. 177: 5296-5306.
54. Sheng, J.R., L.C. Li, B.B. Ganesh, et al. 2008. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia. Clin. Immunol. 128: 172-180.
55. Sheng, J.R., T. Muthusamy, B.S. Prabhakar, et al. 2011. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J. Neuroimmunol. 240-241: 65-73.
56. Rowin, J., M. Thiruppathi, E. Arhebamen, et al. 2012. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: Effects on regulatory T cells. Muscle Nerve 46: 449-453.
57. Adorini, L. & G. Penna. 2009. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 70: 345-352.
58. Battaglia, M., A. Stabilini, B. Migliavacca, et al. 2006. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177: 8338-8347.